Table of Contents Author Guidelines Submit a Manuscript

Insulin Therapies

Call for Papers

The global prevalence of diabetes is astronomical. In 2014, the number of people living with diabetes worldwide was estimated at 422 million and a majority of these people have type 2 diabetes. The prevalence of diabetes has more than tripled over the past 30 years and includes a growing prevalence amongst people residing in low- and middle-income countries. Despite a large armamentarium of drug therapies for diabetes, the mortality associated with it remains significant. In 2012, 1.5 million deaths were attributed to diabetes and elevated blood glucose was deemed to be the cause of another 2.2 million lives lost.

Regardless of diabetes type, insulin is a mainstay of therapy. In the past 5 years, significant improvements have been made to the types of insulin and delivery mechanisms available for use. However, improvements in insulin technology have also raised more questions about optimal use of these newer insulin products, affordability, and the role in therapy of biosimilar and follow-on products.

We invite investigators to contribute original research articles as well as review articles that seek to address a broad range of topics related to insulin therapy for patients with diabetes.

Potential topics include but are not limited to the following:

  • Insulin pricing and affordability
  • Biosimilar and follow-on insulin
  • Insulin and cardiovascular outcomes data
  • Safety, efficacy, and practical use of new basal insulin
  • Safety, efficacy, and practical use of new concentrated insulin
  • Safety, efficacy, and practical use of inhaled insulin
  • Safety, efficacy, and practical use of basal insulin in gestational diabetes
  • Issues related to switching between insulin products
  • Use of insulin in combination with newer oral diabetes agents

Authors can submit their manuscripts through the Manuscript Tracking System at

Submission DeadlineFriday, 24 November 2017
Publication DateApril 2018

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Guest Editors